计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C137735-10mg |
10mg |
现货 ![]() |
| |
| C137735-50mg |
50mg |
现货 ![]() |
| |
| C137735-100mg |
100mg |
现货 ![]() |
| |
| C137735-250mg |
250mg |
现货 ![]() |
| |
| C137735-500mg |
500mg |
现货 ![]() |
| |
| C137735-1g |
1g |
现货 ![]() |
| |
| C137735-5g |
5g |
现货 ![]() |
| |
| C137735-25g |
25g |
现货 ![]() |
|
| 别名 | 克里唑替尼 | 3-[(1R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(4-哌啶)-1H-吡唑-4-基]-2-吡啶胺 | 克唑替尼 | (R)-3-[1-(2,6-二氯-3-氟 - 苯基)-乙氧基]-5-(1-哌啶-4-基-1H-吡唑-4-基)-吡啶-2-基胺 |
|---|---|
| 英文别名 | PF02341066 | PF 2341066 | 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methyl-pyrimidine-2,4-dione | NCGC00250400-09 | BB 0261738 | CRIZOTINIB [MART.] | VGH | CHEBI:64310 | DTXSID40193304 | PF 2341066 | KBio2_002584 | 3-((1R)-1-(2,6-DICHLORO-3- |
| 规格或纯度 | ≥99% |
| 英文名称 | Crizotinib |
| 生化机理 | 克唑替尼(PF-02341066)是受体酪氨酸激酶。 Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). Crizotinib is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.c-MET和间变性淋巴瘤激酶(ALK)受体酪氨酸激酶的强效,xa0ATP竞争性xa0抑制剂(细胞IC 50值分别为8.0和20 nM)。对c-MET和ALK具有针对> 120种不同激酶的选择性。在下列药物中显示抗肿瘤功效 |
| 储存温度 | 2-8°C储存 |
| 运输条件 | 冰袋运输 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM. A Met inhibitor effective against various cell lines Crizotinib has been used: · to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis · to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells · to restore sensitivity to erlotinib PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM. Crizotinib has been used: · to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis · to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells · to restore sensitivity to erlotinib |
| 纯度 | ≥99% |
| ALogP | 3.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488197629 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine |
| INCHI | 1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1 |
| InChi Key | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
| Smiles | CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N |
| Isomeric SMILES | C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N |
| UN Number | 3077 |
| Packing Group | III |
| 分子量 | 450.34 |
| Reaxy-Rn | 12134721 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12134721&ln= |
| 溶解性 | Soluble in DMSO (25 mg/mL warming), ethanol (25 mg/mL warming), methanol, and chloroform. Insoluble in water. |
|---|---|
| 分子量 | 450.300 g/mol |
| XLogP3 | 3.700 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 449.119 Da |
| 单同位素质量Monoisotopic Mass | 449.119 Da |
| 拓扑极表面积Topological Polar Surface Area | 78.000 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 557.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 | |
| 分析证书 | C137735 |
¥335.92
| 1. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, 29 (2). [PMID:37234251] [10.1016/j.jmsacl.2023.05.001] |
| 2. Wang Huai-Song, Xia Xingya, Wang Yingming, Lyu Weiping, Sang Mangmang, Gu Congcong, Liu Wenyuan, Zheng Feng. (2021) Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 413 (28): (6951-6962). [PMID:34676432] [10.1007/s00216-021-03669-x] |
| 3. Zhao-Yang Wang, Hai-Long Wu, Yue-Yue Chang, Tong Wang, Wei Chen, Gao-Yan Tong, Ru-Qin Yu. (2021) Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high-performance liquid chromatography–diode array detection combined with a second-order calibration method. JOURNAL OF SEPARATION SCIENCE, 44 (21): (3914-3923). [PMID:34463059] [10.1002/jssc.202100293] |
| 4. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2021) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, 224 (121798). [PMID:33379025] [10.1016/j.talanta.2020.121798] |